CommercialCoverageMedium impact
08.00.43f, Enfortumab vedotin-ejfv (Padcev®)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Apr 2, 2025
We identified it
Jun 19, 2026
Summary
Insurance policy 08.00.43f for Enfortumab vedotin-ejfv (Padcev®) has been reissued with updates effective April 2, 2025. This is a pharmacy-related policy change that will impact billing and coverage for this cancer medication.
Action Required
By April 2, 2025: Billing team must review the updated policy at the provided URL to understand new requirements for Enfortumab vedotin-ejfv (Padcev®). Update prior authorization processes and billing procedures according to the new policy guidelines. Ensure all staff handling oncology drug billing are aware of changes.